2004 Oct;59(5):479-84
doi: 10.1001/jamanetworkopen.2023.50408 Summary Keywords obesity, anti-obesity pharmacotherapy, emerging therapies, obesity drug development, GLP-1 receptor agonists, combination therapy Citation Park C, Kim Y, Raygani S and Grunvald E (2025) A glimpse into the pipeline of anti-obesity medication development: combining multiple receptor pathways
Why Purity from the Start Matters We've spent a lot of time discussing how to maintain the integrity of your Bac Water
Public school district employee Rebecca Holland sued Its one of a new line of cases filed by the Seattle-based firm Sirianni Youtz Spoonemore Hamburger PLLC against insurers like Elevance, Cigna Health and Life Insurance Co., and Regence BlueShield arguing that the exclusions amount to disability discrimination under antibias laws like Section 1557 of the Affordable Care Act
[DOI] [PMC free article] [PubMed] [Google Scholar] 120.Cho N.Y., Choi M., Kim B.H., Cho Y.M., Moon K.C., Kang G.H
Administration: A 3060-minute infusion in a comfortable, sterile setting
